Insider Transactions in Q2 2023 at Jazz Pharmaceuticals PLC (JAZZ)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 08
2023
|
Seamus Mulligan Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+0.38%
|
$364,500
$81.76 P/Share
|
|
Jun 07
2023
|
Patricia Carr SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
126
-1.97%
|
$16,002
$127.92 P/Share
|
|
Jun 05
2023
|
Kim Sablich EVP, GM of U.S. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,082
-6.81%
|
$268,578
$129.73 P/Share
|
|
Jun 05
2023
|
Robert Iannone EVP, Global Head of R&D |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,311
-2.81%
|
$169,119
$129.73 P/Share
|
|
Jun 01
2023
|
Neena M Patil EVP & Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,600
-2.33%
|
$203,200
$127.99 P/Share
|
|
May 18
2023
|
Renee D Gala President & COO |
SELL
Open market or private sale
|
Direct |
6,000
-14.29%
|
$786,000
$131.75 P/Share
|
|
Apr 05
2023
|
Renee D Gala President & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,807
-4.13%
|
$262,015
$145.78 P/Share
|